<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691613</url>
  </required_header>
  <id_info>
    <org_study_id>WTR-ECG-3</org_study_id>
    <secondary_id>EudraCT 2007-001089-33</secondary_id>
    <nct_id>NCT00691613</nct_id>
  </id_info>
  <brief_title>Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model</brief_title>
  <acronym>IPIIR</acronym>
  <official_title>Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model - A Randomised Cross-over Study to Evaluate if Infusion of a Single Dose of EPO Protects Against Ischemia-reperfusion Injury in Man</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      The investigators hypothesize that EPO protects against apoptosis after acute ischemia in man
      and that it is detectable using the annexin-A5 model.

      Objective:

      Does infusion of a single dose of Epoetin Alfa, a short-acting EPO, protect against apoptosis
      in man after acute ischemia?

      Study design:

      A double blinded randomised cross-over study.

      Study population:

      12 Healthy male volunteers, between 18 and 40 years old.

      Intervention:

      All 12 volunteers will receive a single dose of EPO and placebo in a randomized order. A six
      week wash-out period is obtained in order to avoid interference of both treatments.

      Main study parameters/endpoints:

      The percentage of difference between radioactivity (quantified as counts per pixel) of the
      experimental and control thenar muscle at one and four hours after reperfusion.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of difference between radioactivity (quantified as counts per pixel) of the predefined area of interest of the experimental and control thenar muscle at one and four hours after reperfusion.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DNA polymorphisms affecting HO-1 and AMP-deaminase activity is assessed by DNA analysis.</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of EPO treatment on heme oxygenase activity as measured in blood and as CO concentration in exhaled air.</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal voluntary contraction and duration of the exercise during ischemia.</measure>
    <time_frame>10 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Ischemia-Reperfusion Injury</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alpha</intervention_name>
    <description>The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Eprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Sodiumchloride, saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers between 18 and 40 years of age

          -  male

          -  Volunteers are not allowed smoking 24 hours before the start of the experiment

        Exclusion Criteria:

          -  Female

          -  Hypertension (SBP &gt;140 mmHg, DBP &gt;90 mmHg)

          -  Diabetes Mellitus (DM) (fasting glc &gt;6.9 mmol/l, glc &gt;11.0 mmol/l)

          -  Hypercholesterolemia

          -  Renal dysfunction (eGFR &lt; 60 ml/min, calculated using MDRD formula)

          -  Any known hypersensitivity/allergic reaction to one of the constituents of Epoetin
             Alfa

          -  A history of use of any form of EPO

          -  Any current medication use

          -  Cardiovascular disease in medical history

          -  Smoking less than 24 hours prior to Epoetin alpha infusion

          -  Participation in research in the last 5 years in which any form of radioactivity was
             used

          -  No participation in any research trial in the last 30 days or 5 times the half-life of
             the used substance
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. H. van Gilst, Prof, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Smits, Prof, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Centre Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. T. Ruifrok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. A. Rongen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Centre Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D.J. van Veldhuisen, Prof, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Oyen, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. A. de Boer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P.P. van Geel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. A. Tio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>W. T. Ruifrok, MD</last_name>
    <phone>+31 50 361 6161</phone>
    <phone_ext>77758</phone_ext>
    <email>w.t.ruifok@thorax.umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>R. A. de Boer, MD, PhD</last_name>
    <phone>+31 50 361 6161</phone>
    <phone_ext>12355</phone_ext>
    <email>r.a.de.boer@thorax.umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Centre Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>G. A. Rongen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.umcg.nl</url>
    <description>Webpage of the University Medical Centre Groningen</description>
  </link>
  <link>
    <url>http://www.umcn.nl</url>
    <description>Webpage of the University Medical Centre Nijmegen</description>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>March 11, 2010</last_update_submitted>
  <last_update_submitted_qc>March 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. dr. W.H. van Gilst</name_title>
    <organization>University Medical Centre Groningen, Dept. of Cardiology</organization>
  </responsible_party>
  <keyword>Apoptosis</keyword>
  <keyword>Annexin</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Ischemia-Reperfusion Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

